Here's a cause for optimism, albeit the cautious kind. Researchers at the Cleveland Clinic Lerner Research Institute have managed to isolate a human protein that plays part in the development of breast cancer
, and have produced a vaccine against its creation that has delivered an impressive success rate in testing on mice. In a test group of genetically cancer-prone rodents, none of those injected with á-lactalbumin developed the potentially deadly disease. The progress of this drug trial to testing on humans has been met with reservation by cancer research groups, who remind us that we're years away from knowing if it will actually work on our species. Still, this is quite the little breakthrough and we hope all goes according to plan.